Vulvovaginal graft-versus-værtssygdom: diagnose og mikrobiomvurdering
The goal of this observational study is to investigate the development of vulvovaginal graft-versus-host- disease (GVHD), an under-reported and under-recognized manifestation of chronic GVHD. This study aims to characterize the vaginal microbiome in participants undergoing allogeneic hematopoietic cell transplantation (HCT). The main questions it aims to answer are:
- Is the vaginal microbiome altered during allogeneic HCT?
- What changes may help researchers understand the development of vulvovaginal GVHD?
Participants will be asked to undergo an assessment of vulvovaginal symptoms through a vulvovaginal symptom questionnaire once pre-transplant, 6 months post-transplant, and twelve12 months post- transplant. Participants will also be asked to undergo a vaginal microbiome (collection of bacteria, fungi, and viruses that live on our bodies) evaluation through a vaginal exam performed by a gynecologist with collection of vaginal samples once pre-transplant and again six months post-treatment and twelve months post-transplant. If a participant develops symptoms of vulvovaginal GVHD at any point in time during the post-transplant follow up, the participant may partake in additional vaginal exams to diagnose GVHD at the time of symptom onset.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Recent advances in technologies including high throughput metagenomic 16S rRNA gene sequencing have revealed a larger, more complex picture of the bacterial diversity in the genital tract and unique microbial communities not previously recognized among the known vaginal flora categories. Little is known about how the vaginal microbiome protects the female genital tract or other roles it may have, including interacting with the microbiota of other body sites and subsequent inflammatory responses. Alteration of vaginal flora may play a part in the pathogenesis of diseases by modulating immunity or increasing the growth of pathogenic strains. Recent research has been conducted regarding changes in the vaginal microbiome during various infectious and inflammatory states such as bacterial vaginosis, pelvic inflammatory disease, sexually transmitted infectious, and pregnancy. However, the vaginal microbiome during allogeneic HCT and development of genital GVHD has yet to be examined. Thus, the role of the vaginal microbiome in the development of genital GVHD is a critical area of study.
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiekontakt
- Navn: Betty K Hamilton, MD
- Telefonnummer: 1-866-223-8100
- E-mail: TaussigResearch@ccf.org
Studiesteder
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44195
- Rekruttering
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
-
Kontakt:
- Betty, MD
- Telefonnummer: 866-223-8100
- E-mail: TaussigResearch@ccf.org
-
Ledende efterforsker:
- Betty K Hamilton, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Female participants undergoing allogenic HCT will be recruited from the Blood and Marrow Transplant Program at the Cleveland Clinic.
Beskrivelse
Inclusion Criteria:
- Female participants planning to undergo allogeneic HCT for any disease indication, OR, female participants who have already received HCT and have developed vulvovaginal GVHD during their post-transplant follow-up period
- All conditioning regimens (myeloablative or reduced intensity) will be included.
- All donor sources (HLA matched/mismatched related, unrelated, umbilical cord, haploidentical) will be included.
- All graft sources (bone marrow or peripheral blood stem cells) will be included.
- All GVHD prophylaxis regimens will be included.
- Aged 18-70.
- English speaking and able to sign written informed consent.
- Participants agree to a vaginal gynecologic exam.
- Co-enrollment on other clinical trials will be allowed.
Exclusion Criteria:
- Participants who decline or unable to undergo vaginal gynecologic exam due to any discomfort or pain.
- Any concurrent medical, psychiatric or other illness in which the provider believes the participants may not be able to comply with study assessments.
- Participants with a current diagnosis of a sexually transmitted infection (STI) (Herpes Simplex Virus, Gonorrhea, Chlamydia, Trichomonas,) or a history of previously untreated STI which may incite inflammation that will impact the microbiome.
- Participants with a history of lichen sclerosis, lichen planus, pre-transplant.
- Participants with a history or current diagnosis of vaginal or vulvar malignancy.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
Allogeneic HCT participants
The cohort will be comprised of participants undergoing allogeneic HCT at the Cleveland Clinic. |
Participants will undergo assessment of vulvovaginal symptoms via the vulvovaginal questionnaire once pre-transplant, six months, and develop months post-transplant. A vaginal microbiome evaluation will be performed via vaginal exam by a gynecologist with collection of vaginal samples once pre-transplant, six months, and twelve months post-transplant. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Characterize the vaginal microbiome profile of female participants undergoing allogeneic HCT
Tidsramme: Up to twelve months post-transplant
|
A primary objective of this study is to characterize the vaginal microbiome and in female participants undergoing allogeneic HCT. |
Up to twelve months post-transplant
|
|
Characterize the change in vaginal microbiome profile of female participants undergoing allogeneic HCT
Tidsramme: Up to twelve months post-transplant
|
A primary objective of this study is to characterize the vaginal microbiome change in female participants undergoing allogeneic HCT. |
Up to twelve months post-transplant
|
|
Incidence of vulvovaginal GVHD
Tidsramme: Up to twelve months post-transplant
|
A primary objective is to measure the incidence of vulvovaginal GVHD in this cohort. |
Up to twelve months post-transplant
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Characterize the differences in vaginal microbiome between participants who develop vulvovaginal GVHS versus those who do not
Tidsramme: Up to twelve months post-transplant
|
The secondary objective is to investigate differences in vaginal microbiome between participants who develop vulvovaginal GVHD and those who do not. |
Up to twelve months post-transplant
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Betty K Hamilton, MD, Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CASE2Z24
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .